Human toxocariasis: Current advances in diagnostics, treatment, and interventions

Trends in Parasitology

Volumn 30, Issue 9, 2014, Pages 456-464

  Moreira, Gustavo Marçal Schmidt Garcia ^a   Telmo, Paula de Lima ^a,b   Mendonça, Marcelo ^a   Moreira, Ângela Nunes ^a   McBride, Alan John Alexander ^a   Scaini, Carlos James ^b   Conceição, Fabricio Rochedo ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

Drug modification; Immunodiagnostics; Probiotics; Toxocara canis; Toxocara cati; Toxocariasis

Indexed keywords

ANTHELMINTIC AGENT; DNA VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; PROBIOTIC AGENT; RECOMBINANT PROTEIN;

ANTIBODY DETECTION; DIAGNOSTIC TEST; DNA IMMUNIZATION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NEGLECTED DISEASE; NONHUMAN; PARASITE TRANSMISSION; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TOXOCARA CANIS; TOXOCARA CATI; TOXOCARIASIS; VISCERAL LARVA MIGRANS SYNDROME; WESTERN BLOTTING;

NEMATODA; TOXOCARA CANIS; TOXOCARA CATI;

DRUG MODIFICATION; IMMUNODIAGNOSTICS; PROBIOTICS; TOXOCARA CANIS; TOXOCARA CATI; TOXOCARIASIS;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC TESTS; NEGLECTED DISEASES; PROBIOTICS; TOXOCARIASIS; VACCINES, DNA;

EID: 84906935364     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.07.003     Document Type: Review

References (78)

1. Torgerson P., Budke C. Economic Impact of Toxocara spp. Toxocara The Enigmatic Parasite 2006, 281-293. CABI Publishing. 1st edn. C.V. Holland, H.V. Smith (Eds.).
2. Hotez P.J., Wilkins P.P. Toxocariasis: America's most common neglected infection of poverty and a helminthiasis of global importance?. PLoS Negl. Trop. Dis. 2009, 3:e400.
3. Alderete J.M., et al. Prevalence of Toxocara infection in schoolchildren from the Butanta region, Sao Paulo, Brazil. Mem. Inst. Oswaldo Cruz 2003, 98:593-597.
4. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin. Microbiol. Rev. 2003, 16:265-272.
5. Magnaval J.F., et al. Highlights of human toxocariasis. Korean J. Parasitol. 2001, 39:1-11.
6. Paludo M.L., et al. Frequency of Toxocara infection in children attended by the health public service of Maringa, south Brazil. Rev. Inst. Med. Trop. Sao Paulo 2007, 49:343-348.
7. Fisher M. Toxocara cati: an underestimated zoonotic agent. Trends Parasitol. 2003, 19:167-170.
8. Smith H., et al. How common is human toxocariasis? Towards standardizing our knowledge. Trends Parasitol 2009, 25:182-188.
9. Archelli S., et al. Toxocariasis: seroprevalence in abandoned-institutionalized children and infants. Rev. Argent. Microbiol. 2014, 46:3-6.
10. Baboolal S., Rawlins S.C. Seroprevalence of toxocariasis in schoolchildren in Trinidad. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:139-143.
11. Cassenote A.J., et al. Seroprevalence and modifiable risk factors for Toxocara spp. in Brazilian schoolchildren. PLoS Negl. Trop. Dis. 2014, 8:e2830.
12. Mendonca L.R., et al. Toxocara seropositivity, atopy and wheezing in children living in poor neighbourhoods in urban Latin American. PLoS Negl. Trop. Dis. 2012, 6:e1886.
13. Maraghi S., et al. Study on the contamination of Abadan public parks soil with Toxocara spp. eggs. J. Environ. Health Sci. Eng. 2014, 12:86.
14. Amaral H.L., et al. Presence of Toxocara canis eggs on the hair of dogs: a risk factor for visceral larva migrans. Vet. Parasitol. 2010, 174:115-118.
15. Morimatsu Y., et al. A familial case of visceral larva migrans after ingestion of raw chicken livers: appearance of specific antibody in bronchoalveolar lavage fluid of the patients. Am. J. Trop. Med. Hyg. 2006, 75:303-306.
16. Choi D., et al. Toxocariasis and ingestion of raw cow liver in patients with eosinophilia. Korean J. Parasitol. 2008, 46:139-143.
17. Maffrand R., et al. Congenital ocular toxocariasis in a premature neonate. An. Pediatr. (Barc.) 2006, 64:599-600. (in Spanish).
18. Jin Z., et al. Prolactin evokes lactational transmission of larvae in mice infected with Toxocara canis. Parasitol. Int. 2008, 57:495-498.
19. Reiterova K., et al. Influence of maternal infection on offspring immune response in murine larval toxocariasis. Parasite Immunol. 2003, 25:361-368.
20. Schoenardie E.R., et al. Vertical transmission of Toxocara canis in successive generations of mice. Rev. Bras. Parasitol. Vet. 2013, 22:623-626.
21. Lee A.C., et al. Epidemiologic and zoonotic aspects of ascarid infections in dogs and cats. Trends Parasitol. 2010, 26:155-161.
22. Rubinsky-Elefant G., et al. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. Ann. Trop. Med. Parasitol. 2010, 104:3-23.
23. Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J. Helminthol. 2001, 75:299-305.
24. Demeler J., et al. Discrimination of gastrointestinal nematode eggs from crude fecal egg preparations by inhibitor-resistant conventional and real-time PCR. PLoS ONE 2013, 8:e61285.
25. Durant J.F., et al. Duplex quantitative real-time PCR assay for the detection and discrimination of the eggs of Toxocara canis and Toxocara cati (Nematoda, Ascaridoidea) in soil and fecal samples. Parasit. Vectors 2012, 5:288.
26. Zibaei M., et al. A comparative histopathology, serology and molecular study, on experimental ocular toxocariasis by Toxocara cati in Mongolian gerbils and Wistar rats. Biomed. Res. Int. 2013, 2013:109580.
27. Smith H. Antibody reactivity in human toxocariasis. Toxocara and Toxocariasis: Clinical, Epidemiological, and Molecular Perspectives 1993, 91-109. Institute of Biology and the British Society for Parasitology. J. Lewis, R. Maizels (Eds.).
28. Won K.Y., et al. National seroprevalence and risk factors for zoonotic Toxocara spp. infection. Am. J. Trop. Med. Hyg. 2008, 79:552-557.
29. Fillaux J., Magnaval J.F. Laboratory diagnosis of human toxocariasis. Vet. Parasitol. 2013, 193:327-336.
30. Savigny D.H. In vitro maintenance of Toxocara canis larvae and a simple method for the production of Toxocara ES antigen for use in serodiagnostic tests for visceral larva migrans. J. Parasitol. 1975, 61:781-782.
31. Badley J.E., et al. Analysis of Toxocara canis larval excretory-secretory antigens: physicochemical characterization and antibody recognition. J. Parasitol. 1987, 73:593-600.
32. Sudhakar N.R., et al. Characterization of excretory-secretory antigens of adult Toxocara canis by western blotting. J. Parasit. Dis. 2014, 38:166-169.
33. Bojanich M.V., et al. An evaluation of the dot-ELISA procedure as a diagnostic test in an area with a high prevalence of human Toxocara canis infection. Mem. Inst. Oswaldo Cruz 2012, 107:194-197.
34. Mohamad S., et al. Development and evaluation of a sensitive and specific assay for diagnosis of human toxocariasis by use of three recombinant antigens (TES-26, TES-30USM, and TES-120). J. Clin. Microbiol. 2009, 47:1712-1717.
35. Peixoto P.L., et al. Identification of candidate antigens from adult stages of Toxocara canis for the serodiagnosis of human toxocariasis. Mem. Inst. Oswaldo Cruz 2011, 106:200-206.
36. Magnaval J.F., et al. Application of the western blotting procedure for the immunodiagnosis of human toxocariasis. Parasitol. Res. 1991, 77:697-702.
37. Yamasaki H., et al. Development of a highly specific recombinant Toxocara canis second-stage larva excretory-secretory antigen for immunodiagnosis of human toxocariasis. J. Clin. Microbiol. 2000, 38:1409-1413.
38. Wickramasinghe S., et al. Development of a highly sensitive IgG-ELISA based on recombinant arginine kinase of Toxocara canis for serodiagnosis of visceral larva migrans in the murine model. Parasitol. Res. 2008, 103:853-858.
39. Fong M.Y., Lau Y.L. Recombinant expression of the larval excretory-secretory antigen TES-120 of Toxocara canis in the methylotrophic yeast Pichia pastoris. Parasitol. Res. 2004, 92:173-176.
40. Cereghino J.L., Cregg J.M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 2000, 24:45-66.
41. Yamasaki H., et al. Molecular characterization of a cDNA encoding an excretory-secretory antigen from Toxocara canis second stage larvae and its application to the immunodiagnosis of human toxocariasis. Parasitol. Int. 1998, 47:171-181.
42. Noordin R., et al. Comparison of IgG-ELISA and IgG4-ELISA for Toxocara serodiagnosis. Acta Trop. 2005, 93:57-62.
43. Norhaida A., et al. rTES-30USM: cloning via assembly PCR, expression, and evaluation of usefulness in the detection of toxocariasis. Ann. Trop. Med. Parasitol. 2008, 102:151-160.
44. Jin Y., et al. Serodiagnosis of toxocariasis by ELISA using crude antigen of Toxocara canis larvae. Korean J. Parasitol. 2013, 51:433-439.
45. Elefant G. Toxocaríase. Diagnóstico Laboratorial das Principais Doenças Infecciosas e Autoimunes 2013, 351-362. Guanabara Koogan. 3rd edn. A.W. Ferreira, S. Moraes (Eds.).
46. da Costa de Avila L.F., et al. Evaluation of the immunosuppressive effect of cyclophosphamide and dexamethasone in mice with visceral toxocariasis. Parasitol. Res. 2012, 110:443-447.
47. van Riet E., et al. Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology 2007, 212:475-490.
48. Glickman L.T., Magnaval J.F. Zoonotic roundworm infections. Infect. Dis. Clin. North Am. 1993, 7:717-732.
49. Magnaval J.F., Glickman L.T. Toxocara. Toxocara The Enigmatic Parasite 2006, 113-126. CABI Publishing. 1st edn. C.V. Holland, H.V. Smith (Eds.).
50. Barrera M.G., et al. In vivo evaluation of albendazole microspheres for the treatment of Toxocara canis larva migrans. Eur. J. Pharm. Biopharm. 2010, 75:451-454.
51. Leonardi D., et al. High efficacy of albendazole-PEG 6000 in the treatment of Toxocara canis larva migrans infection. J. Antimicrob. Chemother. 2009, 64:375-378.
52. Horiuchi A., et al. The effect of free and polyethylene glycol-liposome-entrapped albendazole on larval mobility and number in Toxocara canis infected mice. Vet. Parasitol. 2005, 129:83-87.
53. Hrckova G., Velebny S. Treatment of Toxocara canis infections in mice with liposome-incorporated benzimidazole carbamates and immunomodulator glucan. J. Helminthol. 2001, 75:141-146.
54. Satou T., et al. A new method for identifying potential remedies for larva migrans using crude drug extracts (II). Nat. Med. 2003, 57:23-26.
55. Satou T., et al. Toxocara canis: search for a potential drug amongst beta-carboline alkaloids - in vitro and mouse studies. Exp. Parasitol. 2005, 110:134-139.
56. Quesada R., et al. Antiparasitic effect of ethanolic and ethereal extracts of Ficus obtusifolia Kunth (Moraceae) against nematode class parasites (Toxocara cati and Toxocara canis). Infectio 2009, 13:259-267.
57. Musa D., et al. Effects of Nigella sativa and albendazole alone and in combination in Toxocara canis infected mice. J. Pak. Med. Assoc. 2011, 61:866-870.
58. Abo-Shehada M.N., Herbert I.V. Anthelmintic effect of levamisole, ivermectin, albendazole and fenbendazole on larval Toxocara canis infection in mice. Res. Vet. Sci. 1984, 36:87-91.
59. Delgado O., et al. Effect of albendazole in experimental toxocariasis of mice. Ann. Trop. Med. Parasitol. 1989, 83:621-624.
60. Fok E., Kassai T. Toxocara canis infection in the paratenic host: a study on the chemosusceptibility of the somatic larvae in mice. Vet. Parasitol. 1998, 74:243-259.
61. WHO Action to reduce human health hazards arising from animals. WHO Chron. 1978, 32:307-310.
62. Dutra G.F., et al. Evaluation of the initial and chronic phases of toxocariasis after consumption of liver treated by freezing or cooling. Parasitol. Res. 2013, 112:2171-2175.
63. Barriga O.O. A critical look at the importance, prevalence and control of toxocariasis and the possibilities of immunological control. Vet. Parasitol. 1988, 29:195-234.
64. Borchert D., et al. Prevention and treatment of urinary tract infection with probiotics: review and research perspective. Indian J. Urol. 2008, 24:139-144.
65. Coudeyras S., et al. Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis-associated pathogens. Infect. Dis. Obstet. Gynecol. 2008, 2008:549640.
66. Guitard J., et al. Experimental study of the effects of probiotics on Cryptosporidium parvum infection in neonatal rats. Parasitol. Res. 2006, 99:522-527.
67. Humen M.A., et al. Lactobacillus johnsonii La1 antagonizes Giardia intestinalis in vivo. Infect. Immun. 2005, 73:1265-1269.
68. Bautista-Garfias C.R., et al. Effect of viable or dead Lactobacillus casei organisms administered orally to mice on resistance against Trichinella spiralis infection. Parasite 2001, 8:S226-S228.
69. Basualdo J., et al. Oral treatment with a potential probiotic (Enterococcus faecalis CECT 7121) appears to reduce the parasite burden of mice infected with Toxocara canis. Ann. Trop. Med. Parasitol. 2007, 101:559-562.
70. Chiodo P.G., et al. In vitro and in vivo effects of Enterococcus faecalis CECT7121 on Toxocara canis. Mem. Inst. Oswaldo Cruz 2010, 105:615-620.
71. Murray B.E. The life and times of the Enterococcus. Clin. Microbiol. Rev. 1990, 3:46-65.
72. Elmer G.W., McFarland L.V. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol. Clin. North Am. 2001, 30:837-854.
73. Guslandi M., et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 2000, 45:1462-1464.
74. Jett B.D., et al. Virulence of enterococci. Clin. Microbiol. Rev. 1994, 7:462-478.
75. de Avila L.F., et al. Saccharomyces boulardii reduces infection intensity of mice with toxocariasis. Vet. Parasitol. 2012, 187:337-340.
76. Avila L.F., et al. Protective effect of the probiotic Saccharomyces boulardii in Toxocara canis infection is not due to direct action on the larvae. Rev. Inst. Med. Trop. Sao Paulo 2013, 55:363-365.
77. Malheiro A., et al. pcDNA-IL-12 vaccination blocks eosinophilic inflammation but not airway hyperresponsiveness following murine Toxocara canis infection. Vaccine 2008, 26:305-315.
78. Woodhall D.M., et al. Neglected parasitic infections in the United States: toxocariasis. Am. J. Trop. Med. Hyg. 2014, 90:810-813.